Moderna Teases M&A Interest As Pandemic Expected To Wind Down
Biotech Anticipates Four Phase III Programs In Clinic in Q2
Executive Summary
Spikevax revenues beat expectations but analysts are bracing for the eventuality of lower vaccine revenues as COVID-19 becomes endemic. Moderna will have four new vaccines in Phase III this quarter.
You may also be interested in...
First Wave To Merge With ImmunogenX With Focus On Celiac Disease
Troubled by recent clinical disappointments, First Wave will combine with ImmunogenX to focus on that company’s Phase III-ready enzyme replacement therapy for celiac disease. A deep-pocketed partner waits in the wings.
Moderna Highlights Near-Term Non-COVID Readouts As Pandemic Vaccine Sales Drop
The company attributed lower-than-expected vaccine sales to supply issues, but it expects some significant read-outs over the next few months in respiratory infections and oncology.
Coronavirus Update: Pfizer/BioNTech Announce Positive Early Booster Data
The announcement comes amid signs of lagging bivalent booster uptake despite the possibility of a fall and winter surge. Novavax announced data from its combination coronavirus-influenza vaccine, but doubts remain as its approach’s competitiveness against mRNA vaccines. Moderna and Pfizer received EUAs for their bivalent vaccines in young children.